Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $239.77
    -1.78 (-0.74%)

    Market Cap: $15.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jazz Pharmaceuticals PLC (JAZZ) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Jazz Pharmaceuticals reported revenue of $4.27B for the fiscal year ended Dec 31, 2025, up 4.9% from the year before. That year, net income was -$356.15M with a net margin of -8.3%, operating cash flow was $1.36B and free cash flow was $438.97M. The quarter ended Sep 30, 2026 had revenue of $1.24B and net income of -$483.40M.

    Revenue and Margins

    The operating margin was -10.1% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.49B, a compound annual rate of 12.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.27B+4.9%88.2%-10.1%-8.3%
    Dec 2024$4.07B+6.1%89.0%17.6%13.8%
    Dec 2023$3.83B+4.8%88.6%15.1%10.8%
    Dec 2022$3.66B+18.3%85.2%-1.8%-6.1%
    Dec 2021$3.09B+30.9%85.8%5.5%-10.7%
    Dec 2020$2.36B+9.3%93.7%16.0%10.1%
    Dec 2019$2.16B+14.3%94.1%24.6%24.2%
    Dec 2018$1.89B+16.8%93.6%32.5%23.6%
    Dec 2017$1.62B+8.8%93.2%32.7%30.1%
    Dec 2016$1.49BN/A92.9%39.8%26.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B
    Cost of revenue$503.30M$445.71M$435.58M$540.52M$440.76M$148.92M$127.93M$121.54M$110.19M$105.39M
    Gross profit$3.76B$3.62B$3.40B$3.12B$2.65B$2.21B$2.03B$1.77B$1.51B$1.38B
    Research and development$1.73B$894.00M$868.66M$1.03B$505.75M$586.63M$409.70M$226.62M$283.44M$186.05M
    Operating income-$430.24M$716.63M$578.58M-$65.53M$170.28M$378.07M$532.37M$614.84M$528.84M$591.65M
    Net income-$356.15M$560.12M$414.83M-$224.06M-$329.67M$238.62M$523.37M$447.10M$487.85M$396.83M
    EBITDA$263.49M$1.37B$1.23B$544.93M$718.41M$653.05M$896.72M$868.65M$714.05M$730.94M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.24B$1.21B$1.07B$1.20B$1.13B$1.05B$897.80M$1.09B$1.05B$1.02B$901.98M$1.01B
    Gross profit$1.13B$1.09B$934.80M$1.04B$997.20M$929.40M$793.20M$959.46M$943.36M$913.92M$806.50M$904.69M
    Operating income-$413.40M$248.20M$336.60M$254.53M$57.50M-$686.40M-$55.90M$190.77M$260.21M$199.44M$66.21M$122.50M
    Net income-$483.40M$192.80M$293.10M$203.45M$251.40M-$718.50M-$92.50M$191.12M$215.06M$168.57M-$14.62M$94.15M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $5.36B exceeded cash and equivalents by $3.97B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B
    Current assets$4.17B$4.63B$3.44B$2.61B$2.61B$2.84B$1.63B$1.23B$968.28M$748.07M
    Cash and equivalents$1.39B$2.41B$1.51B$881.48M$591.45M$1.06B$637.34M$309.62M$386.04M$365.96M
    Total liabilities$7.34B$7.92B$7.66B$7.75B$8.33B$2.88B$2.43B$2.45B$2.41B$2.92B
    Short-term debt$1.03B$31.00M$604.95M$31.00M$31.00M$246.32M$33.39M$33.39M$40.60M$36.09M
    Long-term debt$4.33B$6.08B$5.11B$5.69B$6.02B$1.85B$1.57B$1.56B$1.54B$1.99B
    Shareholder equity$4.32B$4.09B$3.74B$3.09B$3.97B$3.66B$3.11B$2.76B$2.71B$1.88B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$12.00B$11.08B$11.86B$11.66B$11.36B$10.94B$11.53B$12.01B$12.26B$11.36B$11.33B$11.39B
    Total liabilities$7.81B$6.28B$7.33B$7.34B$7.40B$7.24B$7.36B$7.92B$8.08B$7.60B$7.63B$7.66B
    Cash and equivalents$2.04B$1.62B$1.84B$1.39B$1.33B$1.19B$1.86B$2.41B$2.22B$1.36B$1.44B$1.21B
    Shareholder equity$4.19B$4.80B$4.53B$4.32B$3.96B$3.71B$4.17B$4.09B$4.17B$3.76B$3.70B$3.74B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 32.3% of operating cash flow. Share repurchases came to 28.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.36B$1.40B$1.09B$1.27B$778.51M$899.65M$776.40M$798.90M$693.09M$592.39M
    Capital expenditures$916.80M$38.07M$23.96M$29.05M$27.64M$15.00M$40.13M$20.37M$28.95M$9.69M
    Free cash flow$438.97M$1.36B$1.07B$1.24B$750.87M$884.64M$736.27M$778.53M$664.14M$582.70M
    Dividends paidN/AN/AN/A$98.02M$99.66M$99.68M$57.83MN/A$0$0
    Share repurchases$125.02M$311.43M$269.76M$54.00K$0$146.54M$301.45M$523.67M$98.80M$278.30M
    Investing cash flow-$1.51B-$508.19M-$163.06M-$446.23M-$5.21B-$1.01B-$155.30M-$394.49M-$268.95M-$1.75B
    Financing cash flow-$873.38M$20.52M-$305.25M-$529.49M$3.97B$528.07M-$293.75M-$479.13M-$409.11M$540.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$506.10M$415.70M$408.20M$362.52M$474.70M$88.80M$429.80M$398.58M$398.75M$331.35M$267.23M$167.34M
    Capital expenditures$847.00M$18.10M$96.90M$16.73M$15.20M$871.00M$13.90M$13.29M$10.79M$7.09M$6.90M$10.10M
    Free cash flow-$340.90M$397.60M$311.30M$345.79M$459.50M-$782.20M$415.90M$385.29M$387.96M$324.26M$260.32M$157.24M
    Last 12 quarters

    Frequently Asked Questions About JAZZ

    What is Jazz Pharmaceuticals' annual revenue?

    Jazz Pharmaceuticals reported revenue of $4.27B for the fiscal year ended Dec 31, 2025.

    How fast is Jazz Pharmaceuticals' revenue growing?

    Revenue was up 4.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.3%.

    Is Jazz Pharmaceuticals profitable?

    No. Jazz Pharmaceuticals reported net income of -$356.15M for the fiscal year ended Dec 31, 2025, with a net margin of -8.3%.

    How much free cash flow does JAZZ generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.36B minus capital expenditures of $916.80M produced free cash flow of $438.97M.

    How much debt does Jazz Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $4.33B, short-term debt of $1.03B and cash and equivalents of $1.39B.